Focal Therapy Options for Localized Prostate Cancer

August 2nd 2022

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci, provides a historical perspective on treatment options for clinically localized prostate cancer, reviews emerging focal therapy options including HIFU, and discusses how focal therapy has impacted the field.

Addressing Challenges in Urology Practice Management

July 27th 2022

John J. Kowalczyk, DO, FACOS, shares his experience and perspectives on urology practice management and implementing software tools to improve practice workflows.

Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate Cancer

July 20th 2022

Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.

Implantable Tibial Nerve Stimulation Devices for Treatment of Overactive Bladder

March 2nd 2022

This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.

Lipidosterolic Extract of Serenoa repens (Saw Palmetto) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

January 21st 2022

Expert perspectives on the use of saw palmetto extracts to manage patients with benign prostatic hyperplasia and lower urinary tract symptoms.

Second-Line Treatment Options in Advanced Prostate Cancer

January 21st 2022

Robert Dreicer, MD, provides an overview of advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and available and emerging second-line treatment options for mCRPC.

18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence

December 22nd 2021

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

The Role of Androgen Receptor Inhibitors in the Management of Advanced Prostate Cancer

October 14th 2021

Enteric Hyperoxaluria: Understanding the Disease

June 30th 2021

Kyle Wood, MD, reviews currently available treatment options for enteric hyperoxaluria and the importance of disease education.

The Role of Liquid Biomarker for Early Detection of Prostate Cancer

June 10th 2021

Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.